The HSE has approved reimbursement of Biogen's Skyclarys for Friedreich's ataxia after a substantially improved commercial offer changed the economics of access.

The HSE has approved reimbursement of Biogen's Skyclarys for eligible patients with Friedreich's ataxia, following a substantially improved financial offer from the pharmaceutical company. The decision creates a new reimbursement pathway for an orphan medicine addressing a significant unmet medical need in Ireland.

Biogen is a global biotechnology company focused on neurological and neurodegenerative diseases. Its portfolio includes therapies for multiple sclerosis, Alzheimer's disease and rare neurological conditions, with Skyclarys adding an important rare disease treatment to its commercial footprint.

Skyclarys contains omaveloxolone and is authorised in the EU for adults and adolescents aged 16 and over with Friedreich's ataxia, an inherited condition affecting the nervous system. The European Medicines Agency designated the medicine as an orphan product and concluded that its benefits outweighed its risks when it granted EU marketing authorisation in February 2024.

The strategic significance lies in the distinction between regulatory approval and reimbursement. Skyclarys had already secured European market authorisation, but access through Ireland's public health system required a separate assessment of clinical benefit, cost-effectiveness and commercial value. The National Centre for Pharmacoeconomics completed its assessment in December 2025 and recommended that the medicine not be considered for reimbursement under the terms assessed at that point.

The subsequent change demonstrates how commercial negotiations can alter the market access equation for high-cost rare disease medicines. The HSE said Biogen had moved substantially from its previous position, resulting in a "very different commercial offering" from the terms previously considered by its Drugs Group. The HSE Senior Management Team concluded that the revised proposition justified reimbursement, while also acknowledging the medicine's remaining high cost and limitations in the clinical evidence.

For Biogen, the outcome demonstrates the commercial value of flexibility when entering tightly managed reimbursement markets. For the Irish health system, it shows that sustained negotiation can potentially improve access to innovative medicines while protecting the wider healthcare budget. The HSE specifically said the decision reflected both the substantial unmet need and the absence of another medicine to treat Friedreich's ataxia.

The decision also highlights the growing importance of pricing strategy in rare disease markets. Orphan medicines can address highly specialised patient populations while facing difficult cost-effectiveness assessments because development costs are distributed across relatively small numbers of patients. Ireland's experience with Skyclarys illustrates how evidence assessment and commercial negotiation can operate alongside each other rather than in isolation.

For patients, the decision represents an important step, although access arrangements are not yet fully operational. The HSE said it is continuing discussions with Biogen to finalise the administrative arrangements underpinning reimbursement and intends to progress those discussions quickly.

For the sector, the lesson is direct: securing marketing authorisation is only one part of bringing an innovative medicine to patients. For rare disease therapies in particular, sustainable market access can depend on manufacturers and health systems finding commercial terms that recognise clinical need while remaining workable for public healthcare budgets. Skyclarys shows that constructive negotiation can move that process forward.

Source: RTÉ News / HSE / NCPE / European Medicines Agency